CURIS INC

LEXINGTON, MA · CIK 0001108205 · Biotech · Private

Small molecule HDAC/PI3K inhibitor therapeutics for cancer treatment

curis.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$964K
1 Form D · May 2012
173 months since last filing
Contracts
—
No federal contracts on record
Patents
40
23 granted · 17 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$964,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2572AMPLION INC.—$1.0M
2573Biosceptre International Ltd—$1.0M
2574MATINAS BIOPHARMA, INC.—$1.0M
2575CURIS INC—$964K
2576SUMOCOR, LLC——
2577Thiogenesis Therapeutics, Corp.—$878K
2578Gradient Pharmaceuticals, Inc.—$850K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 11 related persons
  • Susan BayhDirector
  • Michael GrayExecutive Officer
  • Martyn GreenacreDirector
  • Kenneth KaitinDirector
  • Robert MartellDirector
  • James McNab, Jr.Director
  • Mark NoelExecutive Officer
  • Daniel PasseriDirector · Executive Officer
  • Marc RubinDirector
  • James TobinDirector
  • Maurizio VoiExecutive Officer

Patents

USPTO · 23 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.